LSoucekLab

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🔝 #VHIO renova l'acreditació com a Centre d'Excel·lència Severo Ochoa, consolidant el nostre lideratge en recerca oncològica i aposta per transformar la ciència en noves oportunitats per als pacients.

👏 Un reconeixement a totes les persones que fan possible el VHIO. Gràcies‼️

➡️ https://t.co/MmfJezaaDI
#SOMMVhio

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

📣 New VHIO-@CaixaResearch Scientific Seminar‼️

🔹 Targeting clonal heterogeneity in treatment-refractory Glioblastoma with novel and empiric immunotherapies
👩‍🔬 @sheilasinghlab, Head of the School of Cancer & Pharmaceutical Sciences and Director of the Comprehensive Cancer Centre @KingsCollegeLon & Professor at @EvelinaLondon @GSTTnhs
🗓 Friday, 19th June at 12h
🎤 Host: @LauraSoucek

Register at 👉 [email protected]

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

📣 New VHIO-@CaixaResearch Scientific Seminar‼️

🔹 Targeting clonal heterogeneity in treatment-refractory Glioblastoma with novel and empiric immunotherapies
👩‍🔬 @sheilasinghlab, Head of the School of Cancer & Pharmaceutical Sciences and Director of the Comprehensive Cancer Centre @KingsCollegeLon & Professor at @EvelinaLondon @GSTTnhs
🗓 Friday, 19th June at 12h
🎤 Host: @LauraSoucek

Register at 👉 [email protected]

[Laura Soucek @LauraSoucek]

For years, #RAS and #MYC were considered "undruggable." The success of RAS has changed the conversation. Proud to see this recent @Nature News & Views highlighting MYC as a promising next frontier and @Peptomyc as a key player helping advance the field. https://t.co/1lKhk9x8jA

[Laura Soucek @LauraSoucek]

Exciting news for patients and for the oncology community. The Phase 3 #daraxonrasib results in mPDAC show once again that pursuing challenging targets can lead to meaningful clinical advances and that ambitious science is worth the effort.
https://t.co/d9jVhXOkel
#RASi #MYCi

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

Enhorabona!

[Laura Soucek @LauraSoucek]

I always try to say yes to student invitations—my small way to feed forward and support the next generation in science.

Huge thanks to the PhD students who organized the event—fantastic job! Despite train delays and a very late return home, it was absolutely worth it 😊

[Laura Soucek @LauraSoucek]

Last Friday I was an invited speaker at the PhD Day of @IIBM_CSIC / CSIC-UAM / CIBERER / IdiPaz in Madrid.

I talked about the journey toward a clinically viable MYC inhibitor and my path as a researcher (@VHIO, @icreacommunity, @LSoucekLab) and entrepreneur (@peptomyc).

[LSoucekLab @LSoucekLab]

New review out in @FrontImmunol! 🎉
We explore how the oncogene MYC drives immune evasion and resistance to cancer immunotherapy—and why targeting MYC could help restore antitumor immunity.
👉 https://t.co/1LLYjf85KT
@VHIO @icreacommunity @peptomyc

[ICREA Community @icreacommunity]

🗞️Una revisió publicada a @FrontCellDevBio
amb participació de l'#investigadorICREA @LauraSoucek (@VHIO @peptomyc), analitza com la combinació d'inhibidors oncogènics MYC amb teràpies dirigides obre noves oportunitats terapèutiques.
https://t.co/ptPrZpOHs8

[LSoucekLab @LSoucekLab]

We are hiring! If you are interested in joining our Models of Cancer Therapy Laboratory lab at @VHIO as a Research Laboratory Technician / Lab Manager, apply here: https://t.co/xFKJFnj2dX

[Laura Soucek @LauraSoucek]

🎉 New review in @FrontCellDevBio: #MYC in DNA damage response (#DDR) — driver of genomic instability and DNA repair.
Key idea: #MYC inhibition → DDR vulnerabilities → rational combos (#PARP, ATR/CHK1, WEE1).
🔗 https://t.co/jGmRAEYUfD
#MYC #DDR @VHIO @peptomyc @icreacommunity

[LSoucekLab @LSoucekLab]

Una vez más ganadores del primer premio en el concurso de decoración navideña del @VHIO! Como siempre, el trabajo en equipo nos encanta :) Go Team!

[PEPTOMYC @peptomyc]

Ayer @LauraSoucek , nuestra CSO, participó como Keynote Speaker en la 19ª Jornada Científica y 29ª Conferencia Anual del Hospital Vall d’Hebron ✨
Agradecemos al @vallhebron por crear un espacio de intercambio tan enriquecedor.
https://t.co/6hdla6IXvW
#MYC #KeynoteSpeaker

[ICREA Community @icreacommunity]

Un estudi coliderat per la #investigadoraICREA @LauraSoucek (@LSoucekLab) mostra que Omomyc —el fàrmac creat per la spin-off d'ICREA i VHIO @peptomyc— pot ser una estratègia terapèutica per combatre el càncer de mama triple negatiu.

🔗Consulta la notícia: https://t.co/gFEidZnx15

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🧬 Publicado en @CellReports: Combinar el inhibidor de MYC Omomyc con terapias dirigidas a la reparación del ADN potencia la actividad antitumoral en modelos preclínicos de #cáncerdemamatriplenegativo.

🗞️ El estudio está liderado por @LauraSoucek y Fabio Giuntini, del grupo de Modelización de Terapias Antitumorales del VHIO.

@peptomyc, spin-off del VHIO e @icreacommunity, ha desarrollado Omomyc.

➕ https://t.co/kfqDOqGjZ8

[Vall d’Hebron Institute of Oncology (VHIO) @VHIO]

🔴 Recently published in @CellReports, a #VHIO-led study led by @LauraSoucek and Fabio Giuntini shows that combining the MYC inhibitor #Omomyc with DNA-repair–targeted therapies boosts anti-tumor activity in preclinical triple-negative #breastcancer. Omomyc was developed by @peptomyc, the VHIO & @icreacommunity spin-off.

➡️ https://t.co/CmwWtRCIlJ

[LSoucekLab @LSoucekLab]

Exciting news! Our latest study at @VHIO led by Fabio Giuntini & @LauraSoucek in @CellReports shows how Omomyc, the only direct MYC inhibitor in clinical trials, induces DNA damage and overcomes PARP inhibitor resistance in triple-negative breast cancer.
https://t.co/uG8hCtY4vq

[Laura Soucek @LauraSoucek]

Encantada de participar en el Ennova Health Day representando a @VHIO, @icreacommunity y @Peptomyc. Gracias a la organización, @DiarioMedico y a los colegas de mesa por un debate inspirador. La innovación nace en y para el hospital.

[LSoucekLab @LSoucekLab]

End of the week news: Poster presented at the first annual @SOSCLC_AECC Symposium, showcasing preliminary work of @AnaLopezGarza and Hugo Thabussot in #SCLC research, conducted as part of the @ContraCancerEs 70% Survivorship Challenge. @VHIO @peptomyc